GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shuttle Pharmaceuticals Holdings Inc (NAS:SHPH) » Definitions » Tangible Book per Share

SHPH (Shuttle Pharmaceuticals Holdings) Tangible Book per Share : $0.53 (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Shuttle Pharmaceuticals Holdings Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Shuttle Pharmaceuticals Holdings's tangible book value per share for the quarter that ended in Mar. 2025 was $0.53.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Shuttle Pharmaceuticals Holdings Tangible Book per Share Historical Data

The historical data trend for Shuttle Pharmaceuticals Holdings's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shuttle Pharmaceuticals Holdings Tangible Book per Share Chart

Shuttle Pharmaceuticals Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Tangible Book per Share
-1.02 -0.98 4.52 2.02 0.17

Shuttle Pharmaceuticals Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.31 0.38 -0.45 0.17 0.53

Competitive Comparison of Shuttle Pharmaceuticals Holdings's Tangible Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shuttle Pharmaceuticals Holdings's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Shuttle Pharmaceuticals Holdings's Price-to-Tangible-Book falls into.


;
;

Shuttle Pharmaceuticals Holdings Tangible Book per Share Calculation

Shuttle Pharmaceuticals Holdings's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(0.709-0-0)/4.077
=0.17

Shuttle Pharmaceuticals Holdings's Tangible Book Value Per Share for the quarter that ended in Mar. 2025 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(3.285-0-0)/6.258
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Shuttle Pharmaceuticals Holdings  (NAS:SHPH) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Shuttle Pharmaceuticals Holdings Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Shuttle Pharmaceuticals Holdings's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Shuttle Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
N/A
Address
401 Professional Drive, Suite 260, Gaithersburg, MD, USA, 20879
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
Executives
Milton Brown director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Bette Jacobs director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., 1 RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Peter Dritschilo officer: President and COO SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Anatoly Dritschilo director, 10 percent owner, officer: CEO and Chairman SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Tyvin Rich officer: Chief Medical Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Mira Jung officer: Chief Scientific Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Hoek Michael Vander officer: Chief Financial Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Chris Senanayake director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Steven M Richards director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
William Adkins director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Joshua Schafer director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850